Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)

Delayed Quote. Delayed  - 09/23 05:35:07 pm
68.45 EUR   -0.70%
09/21 SANOFI : Files Suit in U.S. to Defend Patent Rights on Lantus and La..
09/21DJMylan CEO Faces Tough Questioning in EpiPen Hearing
09/20 SANOFI : Files Suit in U.S. to Defend Patent Rightson Lantus and Lan..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

SANOFI : EMA Recommends Approval Of Sanofi Pediatric Vaccine Hexyon/Hexacima 6-in-1

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/22/2013 | 01:58pm CEST

PARIS--The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) recommended market approval for Sanofi Pasteur's 6-in-1 pediatric vaccine, French drugs giant Sanofi (>> SANOFI) said Friday.

MAIN FACTS:

- Hexyon/Hexacima is the only fully liquid, ready-to-use, 6-in-1 vaccine to protect infants against diphtheria, tetanus, pertussis (whooping cough), Hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b.

- The new vaccine will be commercialized under the brand name Hexyon in Western European countries by Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur, and under the brand name Hexacima in Eastern European countries by Sanofi Pasteur.

- The vaccine "reduces the number of vaccination visits for infants and it is more convenient for parents to complete the recommended vaccination schedule and thus better protect their children against six major childhood diseases," said Olivier Charmeil, President and CEO of Sanofi Pasteur.

-Hexyon/Hexacima would be indicated for primary and booster vaccination of infants from six weeks of age in accordance with official recommendations.

- The CHMP positive opinion is supported by results of multi-center clinical studies involving approximately 5,000 infants; phase III clinical studies comparing Hexyon/Hexacima to licensed combination vaccines demonstrated that HexyonTM/HexacimaTM is safe and induces a robust immune response against all six targeted diseases.

-Write to Mimosa Spencer at mimosa.spencer@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
09/21 SANOFI : Files Suit in U.S. to Defend Patent Rights on Lantus and Lantus Solosta..
09/21DJMylan CEO Faces Tough Questioning in EpiPen Hearing
09/21 Indian pharma firms in global alliance to fight drug resistance
09/20 SANOFI : Losing steam in the war vs dengue
09/20 SANOFI : Files Suit in U.S. to Defend Patent Rightson Lantus and Lantus Solostar
09/20DJBusiness Watch -- WSJ
09/19 SANOFI : Treatment Effects Maintained Over Six Years in Patients with Relapsing ..
09/19DJSANOFI : Files Suit Against Merck, Claiming Patent Infringements -Update
09/19DJSanofi Files Suit Against Merck
09/19DJSANOFI : Files Suit Against Merck on Patent Infringements -Update
More news
Sector news : Pharmaceuticals - NEC
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
09/23 Endo International CEO steps down, Campanelli named successor
09/23DJSHIRE : Files 8K - Direct Or Off-Balance Sheet Financial Obligation
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09/24 BIOTECH : What's Next For M&A?
09/23 Priority Review Vouchers Revisited
09/23 BIOTECH FORUM DAILY DIGEST : Can Biotech Broach Resistance Levels? Worst Now Ove..
09/22 Biontech Deal Sees Roche Bet On mRNA
09/22 In Teva, Regeneron Finds Its Sanofi For Pain
Advertisement
Financials (€)
Sales 2016 36 923 M
EBIT 2016 9 287 M
Net income 2016 5 275 M
Debt 2016 5 441 M
Yield 2016 4,30%
P/E ratio 2016 15,70
P/E ratio 2017 14,39
EV / Sales 2016 2,54x
EV / Sales 2017 2,54x
Capitalization 88 235 M
More Financials
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 25
Average target price 82,8 €
Spread / Average Target 21%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias E. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-12.91%99 053
JOHNSON & JOHNSON15.66%325 050
ROCHE HOLDING LTD.-11.18%218 395
NOVARTIS AG-8.70%214 744
PFIZER INC.6.13%207 809
MERCK & CO., INC.19.20%174 098
More Results